Rising Incidence of Type 1 Diabetes Is Associated With Altered Immunophenotype at Diagnosis
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
The incidence of type 1 diabetes has increased rapidly over recent decades, particularly in young children. We aimed to determine whether this rise was associated with changes in patterns of humoral islet autoimmunity at diagnosis. Autoantibodies to insulin (IAA), GAD (GADA), islet antigen-2 (IA-2A), and zinc transporter 8 (ZnT8A) were measured by radioimmunoassay in sera collected from children and young adults with newly diagnosed type 1 diabetes between 1985 and 2002. The influence of date of diagnosis on prevalence and level of autoantibodies was investigated by logistic regression with adjustment for age and HLA class II genetic risk. Prevalence of IA-2A and ZnT8A increased significantly over the period studied, and this was mirrored by raised levels of IA-2A, ZnT8A, and IA-2β autoantibodies (IA-2βA). IAA and GADA prevalence and levels did not change. Increases in IA-2A, ZnT8A, and IA-2βA at diagnosis during a period of rising incidence suggest that the process leading to type 1 diabetes is now characterized by a more intense humoral autoimmune response. Understanding how changes in environment or lifestyle alter the humoral autoimmune response to islet antigens should help explain why the incidence of type 1 diabetes is increasing and may suggest new strategies for preventing disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The prevalence of IA‐2βA and autoantibodies recognizing the protein tyrosine phosphatase region of IA‐2 (PTPA) also increased during this time‐span.”
From Islet autoantibody profiles associated with higher diabetes risk in Lithuanian compared with English schoolchildren (2020) · cites this paper as [8]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The thresholds used to assign antibody positivity for IA‐2‐related antibodies have been previously published applied to newly diagnosed children [8]; nevertheless, they were set using different populations of healthy individuals.”
From Islet autoantibody profiles associated with higher diabetes risk in Lithuanian compared with English schoolchildren (2020) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“We previously investigated autoantibody prevalence at diagnosis in patients from the same geographical region as the English schoolchildren during a 17‐year time‐span, when type 1 diabetes incidence rose and prevalence of ZnT8A and IA‐2A increased [ 8 ].”
From Islet autoantibody profiles associated with higher diabetes risk in Lithuanian compared with English schoolchildren (2020) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Patterson, C. C., Dahlquist, G. G., Gyürüs, E., Green, A., & Soltész, G. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60568-7 · Cited by 1,854 · cited 1×
“The incidence of type 1 diabetes is rising by 3–4% per year across Europe, North America, and Australia, with the greatest increase in children diagnosed at ,5 years of age (1,2).”
BackgroundThe cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes
Wenzlau, J. M., Juhl, K., Yu, L., Moua, O., Sarkar, S. A., Gottlieb, P., Rewers, M., Eisenbarth, G. S., Jensen, J., Davidson, H. W., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705894104 · Cited by 1,014
The accelerator hypothesis: weight gain as the missing link between type I and type II diabetes
Wilkin, T. J. (2001) · Diabetologia · doi:10.1007/s001250100548 · Cited by 623 · cited 1×
“Lifestyle changes could therefore play a role in stimulating autoantibody production through increased islet autoantigen expression (20,21), but there are currently no data directly supporting this association (22).”
BackgroundBingley, P. J., Bonifacio, E., Williams, A. J. K., Genovese, S., Bottazzo, G. F., & Gale, E. A. M. (1997) · Diabetes · doi:10.2337/diab.46.11.1701 · Cited by 461
Self-citationPrediction and Pathogenesis in Type 1 Diabetes
Ziegler, A.-G., & Nepom, G. T. (2010) · Immunity · doi:10.1016/j.immuni.2010.03.018 · Cited by 346 · cited 3×
“The antibodies that increased over the study period, IA-2A and ZnT8A, usually appear after GADA and IAA (6).”
BackgroundGillespie, K. M., Bain, S. C., Barnett, A. H., Bingley, P. J., Christie, M. R., Gill, G. V., & Gale, E. A. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17357-1 · Cited by 304
Self-citationBonifacio, E., Yu, L., Williams, A. K., Eisenbarth, G. S., Bingley, P. J., Marcovina, S. M., Adler, K., Ziegler, A. G., Mueller, P. W., Schatz, D. A., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0293 · Cited by 291 · cited 1×
“and IA-2A in DK units/mL (14) derived from standard curves, with extrapo-”
MethodSelf-citationGardner, S. G., Bingley, P. J., Sawtell, P. A., Weeks, S., & Gale, E. A. (1997) · BMJ · doi:10.1136/bmj.315.7110.713 · Cited by 242
Self-citationLambert, A. P., Gillespie, K. M., Thomson, G., Cordell, H. J., Todd, J. A., Gale, E. A. M., & Bingley, P. J. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032084 · Cited by 241
Self-citationAntiislet autoantibodies usually develop sequentially rather than simultaneously
Yu, L. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.12.4264 · Cited by 214 · cited 2×
“As islet autoimmunity evolves, there is typically spreading of reactivity to different target autoantigens and epitopes (5).”
Background
Research works printed but not linked: 1
- 24. Ali K Wilson IV Edge JA Bingley PJ Diabetic ketoacidosis at diagnosis has not declined in children over the last 20 years: data from the Bart’s-Oxford Study (Abstract). Diabet Med 2009; 26 (Suppl. 1): 3419125758
Cited by
Athyros, V. G., Doumas, M., Imprialos, K. P., Stavropoulos, K., Georgianou, E., Katsimardou, A., & Karagiannis, A. (2018) · Hormones · doi:10.1007/s42000-018-0014-8 · Cited by 367
Environmental and genetic contributions to diabetes
Tremblay, J., & Hamet, P. (2019) · Metabolism · doi:10.1016/j.metabol.2019.153952 · Cited by 163
Bravis, V., Kaur, A., Walkey, H. C., Godsland, I. F., Misra, S., Bingley, P. J., Williams, A. J. K., Dunger, D. B., Dayan, C. M., Peakman, M., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-020904 · Cited by 91
Self-citationAdvances in the cellular immunological pathogenesis of type 1 diabetes
Li, M., Song, L., & Qin, X. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12270 · Cited by 93
“Autoantibodies directed against islet autoantigens such as insulin, glutamic acid decarboxylase 65 (GAD 65), islet antigen-2 (IA-2) and Zinc transporter 8 (ZnT8) have been demonstrated to be markers of the islet autoimmunity that precede clinical onset of T1D [9, 10] (Fig.”
BackgroundVehik, K., Bonifacio, E., Lernmark, Å., Yu, L., Williams, A., Schatz, D., Rewers, M., She, J.-X., Toppari, J., Hagopian, W., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2547 · Cited by 87
Self-citationThe Genetic Architecture of Type 1 Diabetes
Jerram, S. T., & Leslie, R. D. (2017) · Genes · doi:10.3390/genes8080209 · Cited by 94
“One study of diabetes carried out between 1985 and 2002 found that the prevalence of Islet Antigen-2 autoantibodies (IA-2A) and Zinc Transporter-8 autoantibodies (ZnT8A) increased significantly in that period, with raised levels of IA-2A, ZnT8A, and IA-2β autoantibodies also seen [12].”
BackgroundYazdanpanah, N., Yazdanpanah, M., Wang, Y., Forgetta, V., Pollak, M., Polychronakos, C., Richards, J. B., & Manousaki, D. (2021) · Diabetes Care · doi:10.2337/dc21-1049 · Cited by 74
Husseiny, M. I., Kuroda, A., Kaye, A., Nair, I., KANDEEL, F. R., & Ferreri, K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047942 · Cited by 67
Kozhakhmetova, A., Wyatt, R. C., Caygill, C., Williams, C., Long, A. E., Chandler, K., Aitken, R. J., Wenzlau, J. M., Davidson, H. W., Gillespie, K. M., et al. (2018) · Clinical and Experimental Immunology · doi:10.1111/cei.13115 · Cited by 46
Self-citationNiechciał, E., Rogowicz‐Frontczak, A., Piłaciński, S., Fichna, M., Skowrońska, B., Fichna, P., & Zozulińska‐Ziółkiewicz, D. (2018) · Acta Diabetologica · doi:10.1007/s00592-017-1091-x · Cited by 50
“[25] reported the rise of IA2-ab and ZnT8-ab prevalence, while GAD-ab and IAA remained stable.”
Xiang, Y., Huang, G., Shan, Z., Pan, L., Luo, S., Yang, L., Shi, L., Li, Q., Leslie, R. D., & Zhou, Z. (2015) · Acta Diabetologica · doi:10.1007/s00592-015-0799-8 · Cited by 42
Type 1 diabetes in Africa: an immunogenetic study in the Amhara of North-West Ethiopia
Balcha, S. A., Demisse, A. G., Mishra, R., Vartak, T., Cousminer, D. L., Hodge, K. M., Voight, B. F., Lorenz, K., Schwartz, S., Jerram, S. T., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05229-x · Cited by 41
Self-citationRole of humoral beta-cell autoimmunity in type 1 diabetes
Knip, M., Siljander, H., Ilonen, J., Simell, O., & Veijola, R. (2016) · Pediatric Diabetes · doi:10.1111/pedi.12386 · Cited by 49
What has zinc transporter 8 autoimmunity taught us about type 1 diabetes?
Williams, C. L., & Long, A. E. (2019) · Diabetologia · doi:10.1007/s00125-019-04975-x · Cited by 39
Self-citationRedondo, M. J., Muniz, J., Rodriguez, L. M., Iyer, D., Vaziri-Sani, F., Haymond, M. W., Hampe, C. S., Metzker, M. L., Grant, S. F. A., & Balasubramanyam, A. (2014) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2013-000008 · Cited by 34
Arif, S., Gibson, V. B., Nguyen, V., Bingley, P. J., Todd, J. A., Guy, C., Dunger, D. B., Dayan, C. M., Powrie, J., Lorenc, A., et al. (2016) · Diabetic Medicine · doi:10.1111/dme.13153 · Cited by 36
“Autoantibodies to glutamic acid decarboxylase 65 (GAD65), intracytoplasmic (606–979) islet antigen 2 (IA-2) and zinc transporter 8 (ZnT8) were measured by radioimmunoassay [8,9].”
MethodSelf-citationHanna, S. J., Powell, W. E., Long, A. E., Robinson, E. J. S., Davies, J. E., Megson, C., Howell, A., Jones, T. J., Ladell, K., Price, D. A., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05114-7 · Cited by 34
Self-citationWilliams, A. J. K., Lampasona, V., Wyatt, R. C., Brigatti, C., Gillespie, K. M., Bingley, P. J., & Achenbach, P. (2015) · Diabetes · doi:10.2337/db14-1694 · Cited by 36
Self-citationTargeting innate immunity to downmodulate adaptive immunity and reverse type 1 diabetes
Itoh, A., & Ridgway, W. M. (2017) · ImmunoTargets and Therapy · doi:10.2147/itt.s117264 · Cited by 32
“One impetus for considering prevention is the rapid increase in T1D incidence in many countries since the mid-20th century, which is not explicable by the known genetic predisposition to disease.(26) In Europe, for example, the incidence of T1D cases has been increasing on the average 3.”
Persistence of islet autoantibodies after diagnosis in type 1 diabetes
Long, A. E., George, G., & Williams, C. L. (2021) · Diabetic Medicine · doi:10.1111/dme.14712 · Cited by 31
Self-citationWilliams, C. L., Fareed, R., Mortimer, G., Aitken, R. J., Wilson, I. V., George, G., Gillespie, K. M., Williams, A. J. K., The BOX Study Group, Ballav, C., et al. (2022) · Clinical & Experimental Immunology · doi:10.1093/cei/uxac087 · Cited by 31
Self-citationReversal of New-Onset Type 1 Diabetes With an Agonistic TLR4/MD-2 Monoclonal Antibody
Bednar, K. J., Tsukamoto, H., Kachapati, K., Ohta, S., Wu, Y., Katz, J. D., Ascherman, D. P., & Ridgway, W. M. (2015) · Diabetes · doi:10.2337/db14-1868 · Cited by 27
“The incidence of T1D has risen rapidly worldwide since the mid-20 th century, increasing by 34% per annum in Europe and the United States (8-11).”
BackgroundVirus induced dysbiosis promotes type 1 diabetes onset
Morse, Z. J., Simister, R. L., Crowe, S. A., Horwitz, M. S., & Osborne, L. C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1096323 · Cited by 26
Innate Viral Receptor Signaling Determines Type 1 Diabetes Onset
Morse, Z. J., & Horwitz, M. S. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00249 · Cited by 25
“8% annually from 2002 to 2012 worldwide (10, 11).”
Incidence of Type 1 Diabetes in Mexico: Data From an Institutional Register 2000–2010
Gómez-Díaz, R. A., Pérez-Pérez, G., Hernández-Cuesta, I. T., Rodríguez-García, J. D. C., Guerrero-López, R., Aguilar-Salinas, C. A., & Wacher, N. H. (2012) · Diabetes Care · doi:10.2337/dc12-0844 · Cited by 24
“Perinatal infections, weight increase in the first months of life, and increase in maternal age are among the potential explanations (3,4).”
BackgroundLong, A. E., Gillespie, K. M., Aitken, R. J., Goode, J. C., Bingley, P. J., & Williams, A. J. K. (2013) · Diabetes · doi:10.2337/db12-1468 · Cited by 25
Self-citationWilliams, C. L., Marzinotto, I., Brigatti, C., Gillespie, K. M., The BOX Study Group, Wilson, I. S., Aitken, R. J., Megson, C., Ballav, C., Dutta, A. K., et al. (2023) · Clinical & Experimental Immunology · doi:10.1093/cei/uxad139 · Cited by 20
“Autoantibodies to ZnT8 [aa268-369; ZnT8-R325 and ZnT8-W325 peptides] were detected by monomeric RBAs described previously [26].”
BackgroundSelf-citationFour decades of the Bart’s Oxford study: Improved tests to predict type 1 diabetes
Gillespie, K. M., Fareed, R., & Mortimer, G. (2021) · Diabetic Medicine · doi:10.1111/dme.14717 · Cited by 17
Self-citationFrom Markers to Molecular Mechanisms: Type 1 Diabetes in the Post-GWAS Era
Baxter, A. G., & Jordan, M. A. (2012) · The Review of Diabetic Studies · doi:10.1900/rds.2012.9.201 · Cited by 17
“These trends are consistent with changing environmental effects on the pathogenesis of the disease [8-9].”
BackgroundBenghalem, I., Meziane, W., Hadjidj, Z., Ysmail-Dahlouk, L., Belamri, A., Mouhadjer, K., & Aribi, M. (2017) · Cytokine · doi:10.1016/j.cyto.2017.03.001 · Cited by 17
“It has been reported that autoreactive T cells differentiate into effectors by engaging b-cell antigens on local antigen-presenting cells (APCs) [6].”
BackgroundActivated but functionally impaired memory Tregs are expanded in slow progressors to type 1 diabetes
Boldison, J., Long, A. E., Aitken, R. J., Wilson, I. V., Megson, C., Hanna, S. J., Wong, F. S., & Gillespie, K. M. (2021) · Diabetologia · doi:10.1007/s00125-021-05595-0 · Cited by 15
Self-citationWacher, N. H., Gómez-Díaz, R. A., Ascencio-Montiel, I. D. J., Rascón-Pacheco, R. A., Aguilar-Salinas, C. A., & Borja‐Aburto, V. H. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107949 · Cited by 16
McLaughlin, K. A., Richardson, C. C., Williams, S. R., Bonifacio, E. E., Morgan, D., Feltbower, R. G., Powell, M. J., Smith, B. R., Furmaniak, J., & Christie, M. R. (2015) · Clinical Immunology · doi:10.1016/j.clim.2015.06.002 · Cited by 14
“Recent studies have shown an increase in the prevalence of antibodies to epitopes in the IA-2 PTP domain, concurrent with rising diabetes prevalence [23,24].”
BackgroundElvers, K. T., Geoghegan, I. A., Shoemark, D. K., Lampasona, V., Bingley, P. J., & Williams, A. J. K. (2012) · Diabetes · doi:10.2337/db11-1590 · Cited by 13
“Identifying the determinants of the IA-2A response will help to clarify their importance to disease pathogenesis, particularly as IA-2A prevalence in patients may be increasing in parallel with the rising incidence of type 1 diabetes (39).”
BackgroundSelf-citationHörtenhuber, T., Kieß, W., Fröhlich-Reiterer, E. E., Raile, K., Stachow, R., Bollow, E., Rami-Merhar, B. M., Holl, R. W., & on behalf of the DPV-Wiss Study Group (2017) · Pediatric Diabetes · doi:10.1111/pedi.12618 · Cited by 11
Lu, T., Manousaki, D., Sun, L., & Paterson, A. D. (2025) · Diabetes · doi:10.2337/db24-0380 · Cited by 9
Ingemansson, S., Vaziri‐Sani, F., Lindblad, U., Guðbjörnsdóttir, S., Törn, C., & on Behalf of the Diss-Study Group (2012) · Autoimmunity · doi:10.3109/08916934.2012.730585 · Cited by 9
“ZnT8A was detected in 64% of patients diagnosed from 1985 to 1990 compared with 74% in patients diagnosed from 1997 to 2002 [27].”
ResultFuentes, S., Rodríguez, C. G., Rodríguez-Chacón, C., Toribio, R. G., Hermosín-Escudero, J., Pérez‐Pérez, A., & León‐Justel, A. (2023) · Laboratory Medicine · doi:10.1093/labmed/lmad079 · Cited by 9
Rostami, P., Setoodeh, A., Rabbani, A., Nakhaeimoghadam, M., Najmi-Varzaneh, F., & Rezaei, N. (2014) · PubMed · Cited by 8
Donnelly, C., & Williams, A. J. K. (2020) · Metabolism Open · doi:10.1016/j.metop.2020.100062 · Cited by 8
Self-citationThorsen, S. U., Pipper, C. B., Mortensen, H. B., Pociot, F., Johannesen, J., & Svensson, J. (2016) · International Journal of Endocrinology · doi:10.1155/2016/8350158 · Cited by 7
Besser, R. E. J., Long, A. E., Owen, K. R., Law, R., Birks, J., Pearce, O., Williams, C. L., Scudder, C. L., McDonald, T. J., & Todd, J. A. (2023) · Diabetes Care · doi:10.2337/dc23-1379 · Cited by 6
Self-citationTargeting Innate Immunity for Treatment of Type 1 Diabetes
Bednar, K. J., & Ridgway, W. M. (2014) · Immunotherapy · doi:10.2217/imt.14.96 · Cited by 6
Baumann, K., Kesselring, K., Lampasona, V., Walschus, U., Kerner, W., Waßmuth, R., & Schlosser, M. (2020) · Diabetic Medicine · doi:10.1111/dme.14389 · Cited by 6
Genetic Predisposition, Humans
Jordan, M. A., Field, J., Butzkueven, H., & Baxter, A. G. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-384929-8.00026-5 · Cited by 7
Wallington, D. G., Schauer, M., & Bauler, L. D. (2019) · BMJ Case Reports · doi:10.1136/bcr-2018-227554 · Cited by 5
Genetic Predisposition, Humans
Jordan, M. A., & Baxter, A. G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812102-3.00023-3 · Cited by 6
Christie, M. R. (2016) · Diabetes · doi:10.2337/dbi16-0008 · Cited by 4
“Furthermore, a study of islet autoantibodies in patients with diabetes showed increasing prevalence of IA-2 and ZnT8 antibodies over a 17-year period, whereas antibodies to insulin did not change (7).”
BackgroundHedlund, E., Maziarz, M., Lindahl, T. L., Elding-Larsen, H., Forsander, G., Persson, M., Pundziūtė-Lyckå, A., Åkesson, K., Ludvigsson, J., & Carlsson, A. (2025) · Diabetes Care · doi:10.2337/dc25-0840 · Cited by 3
Long, A. E., Caygill, C. H., Gillespie, K. M., Marčiulionytė, D., & Williams, A. J. K. (2020) · Clinical and Experimental Immunology · doi:10.1111/cei.13524 · Cited by 1
Self-citationWyatt, R. C., Brigatti, C., Grace, S. L., Williams, C. L., Marzinotto, I., Gillard, B. T., Bazzigaluppi, E., Shoemark, D. K., Chandler, M. A. ‐., Achenbach, P., et al. (2026) · Diabetic Medicine · doi:10.1111/dme.70277 · Cited by 1
Self-citationRole of ERK5 in Diabetic Vascular Complications
Wu, Y. (2012) · Scholarship@Western (Western University) · Cited by 1
Epidemiology of Type 1 Diabetes Complications in African-Americans
Washington, R. (2012) · D-Scholarship@Pitt (University of Pittsburgh)
Examining the barriers and benefits to exercise in adults with newly diagnosed type 1 diabetes
Kennedy, A. (2017) · University of Birmingham Institutional Research Archive (University of Birmingham)
Aspectos demográficos de una muestra de pacientes colombianos con diabetes mellitus tipo 1
Yepes, D. C. S., Gómez-Lopera, N., García, J., Lopera, M. V., Toro, M., Vélez, A., Alfaro, J. M. E., & Pineda-Trujillo, N. (2017) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.4.4.146
Effet de la vitamine D3 sur la modulation des balances immunologiques au début du diabète de type 1
Ysmail, D. L. (2017) · Dépôt Institutionnel de lUniversité de Tlemcen · Cited by 1
Exocrine Proteins Including Trypsin(ogen) as a Key Biomarker in Type 1 DiabetesPreprint
Bakinowska, L., Vartak, T., Phuthego, T., Taylor, M. R., Chandler, K. A., Jerram, S. T., The BOX Study Group, Williams, S., Feldmann, M., Johnston, D. G., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4106538
Self-citationExocrine proteins including Trypsin(ogen) as a key biomarker in type 1 diabetes
Bakinowska, L., Vartak, T., Phuthego, T., Taylor, M., Chandler, K. A., Jerram, S. T., Williams, S., Feldmann, M., Johnson, D. G., Patel, K., et al. (2023) · doi:10.2337/figshare.21801124
Self-citationExocrine proteins including Trypsin(ogen) as a key biomarker in type 1 diabetes
Bakinowska, L., Vartak, T., Phuthego, T., Taylor, M., Chandler, K. A., Jerram, S. T., Williams, S., Feldmann, M., Johnson, D. G., Patel, K., et al. (2023) · doi:10.2337/figshare.21801124.v2
Self-citationEvaluation of distinct and similar pathological features between diabetes and Alzheimer’s disease
Reed, J., Bain, S. C., & Kanamarlapudi, V. (2026) · EXCLI journal · doi:10.17179/excli2026-9429
Williams, C. L., Rokni, S., Lampasona, V., Brigatti, C., Gillard, B. T., Gillespie, K. M., Williams, A. J. K., & Long, A. E. (2026) · Clinical & Experimental Immunology · doi:10.1093/cei/uxag050
“Autoantibodies to wild-type and mutant ZnT8 were detected by RBA, as described previously [25].”
Self-citation
Metadata
- Authors
- Long, A. E., Gillespie, K. M., Rokni, S., Bingley, P. J., & Williams, A. J. K.
- Affiliations
- University of Bristol (GB)
- Corresponding author
- Williams, Alistair J.K.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2012-02-13
- Volume
- 61
- Issue
- 3
- Pages
- 683-686
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3282823
- OpenAlex
- W2098405716
- Cited by
- 60
- References
- 25
- Citations by year
- 2026: 1 · 2025: 2 · 2023: 7 · 2022: 3 · 2021: 4 · 2020: 6 · 2019: 5 · 2018: 4 · 2017: 7 · 2016: 4 · 2015: 4 · 2014: 4 · 2013: 2 · 2012: 7
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Bristol Research (University of Bristol) (publishedVersion)
- Explore Bristol Research (submittedVersion)
- Funders
- Wellcome Trust
- University of Bristol
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- type 1 diabetes, incidence trends, humoral autoimmunity, islet autoantibodies, IA-2 autoantibodies, zinc transporter 8 autoantibodies, insulin autoantibodies, glutamic acid decarboxylase antibodies, immunophenotype, children and young adults, HLA class II, disease prevention
- MeSH terms
- Zinc Transporter 8, Adolescent, Adult, Autoantibodies, Child, Child, Preschool, Diabetes Mellitus, Type 1, Female, Humans, Infant, Male, Logistic Models, Immunophenotyping, Cation Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.